"Immunotransplants May Enhance Efficacy Of Checkpoint Blockade Immunotherapy For Treating Resistant Lymphomas" - John Schieszer
Researchers at the Icahn School of Medicine at Mount Sinai are reporting that that it may be possible to use immunotransplants to enhance the efficacy of checkpoint blockade immunotherapy for treating disease-resistant lymphomas. The team has developed a way to use immunotherapy drugs against treatment-resistant non-Hodgkin's lymphomas for the first time by combining them with stem cell transplantation. Study investigator Joshua Brody, MD, director of the Lymphoma Immunotherapy Program at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai says using immunotransplants to enhance the efficacy of checkpoint blockade therapy could be broadly significant as these immunotherapies are standard therapies for melanoma, kidney cancer, lung cancer, and other tumor types.
— Joshua Brody, MD, Director, Lymphoma Immunotherapy Program, The Tisch Cancer Institute, Assistant Professor, Medicine, Hematology, Medical Oncology, Icahn School of Medicine at Mount Sinai
Mount Sinai Researchers Make Immunotherapy Work for Treatment-Resistant Lymphoma
Aug 02, 2019 View All Press Releases